Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Fundamental Analysis

NASDAQ:SCPH - Nasdaq - US8106481059 - Common Stock - Currency: USD

2.61  +0.05 (+1.95%)

Premarket: 2.5 -0.11 (-4.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SCPH. SCPH was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCPH have multiple concerns. SCPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCPH had negative earnings in the past year.
In the past year SCPH has reported a negative cash flow from operations.
SCPH had negative earnings in each of the past 5 years.
In the past 5 years SCPH always reported negative operating cash flow.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SCPH has a worse Return On Assets (-79.19%) than 71.21% of its industry peers.
SCPH has a Return On Equity of -639.25%. This is in the lower half of the industry: SCPH underperforms 79.29% of its industry peers.
Industry RankSector Rank
ROA -79.19%
ROE -639.25%
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

With a decent Gross Margin value of 68.73%, SCPH is doing good in the industry, outperforming 73.74% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SCPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCPH has more shares outstanding than it did 1 year ago.
SCPH has more shares outstanding than it did 5 years ago.
SCPH has a worse debt/assets ratio than last year.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SCPH has an Altman-Z score of -4.57. This is a bad value and indicates that SCPH is not financially healthy and even has some risk of bankruptcy.
SCPH's Altman-Z score of -4.57 is on the low side compared to the rest of the industry. SCPH is outperformed by 60.61% of its industry peers.
SCPH has a Debt/Equity ratio of 3.86. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SCPH (3.86) is worse than 81.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.86
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC10.93%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SCPH has a Current Ratio of 7.12. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SCPH (7.12) is better than 77.27% of its industry peers.
A Quick Ratio of 6.18 indicates that SCPH has no problem at all paying its short term obligations.
The Quick ratio of SCPH (6.18) is better than 76.77% of its industry peers.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 6.18
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

SCPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.80%.
Looking at the last year, SCPH shows a very strong growth in Revenue. The Revenue has grown by 167.23%.
EPS 1Y (TTM)-33.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)167.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.31%

3.2 Future

The Earnings Per Share is expected to grow by 24.40% on average over the next years. This is a very strong growth
Based on estimates for the next years, SCPH will show a very strong growth in Revenue. The Revenue will grow by 52.16% on average per year.
EPS Next Y47.38%
EPS Next 2Y37.44%
EPS Next 3Y32.85%
EPS Next 5Y24.4%
Revenue Next Year110.33%
Revenue Next 2Y93.19%
Revenue Next 3Y76.78%
Revenue Next 5Y52.16%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

SCPH's earnings are expected to grow with 32.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y32.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCPHARMACEUTICALS INC

NASDAQ:SCPH (4/22/2025, 8:00:01 PM)

Premarket: 2.5 -0.11 (-4.21%)

2.61

+0.05 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners67.7%
Inst Owner Change0.04%
Ins Owners6.88%
Ins Owner Change-3.38%
Market Cap131.23M
Analysts85
Price Target15.47 (492.72%)
Short Float %18.12%
Short Ratio15.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.34%
Min EPS beat(2)-147.99%
Max EPS beat(2)9.3%
EPS beat(4)2
Avg EPS beat(4)-30.91%
Min EPS beat(4)-147.99%
Max EPS beat(4)19.24%
EPS beat(8)5
Avg EPS beat(8)-11.39%
EPS beat(12)8
Avg EPS beat(12)-5.3%
EPS beat(16)12
Avg EPS beat(16)0.89%
Revenue beat(2)0
Avg Revenue beat(2)-5.21%
Min Revenue beat(2)-9%
Max Revenue beat(2)-1.43%
Revenue beat(4)1
Avg Revenue beat(4)-2.82%
Min Revenue beat(4)-9%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)6.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.78%
PT rev (3m)-13.33%
EPS NQ rev (1m)6.88%
EPS NQ rev (3m)-1.59%
EPS NY rev (1m)-1.03%
EPS NY rev (3m)-1.03%
Revenue NQ rev (1m)-9.39%
Revenue NQ rev (3m)-19.43%
Revenue NY rev (1m)-8.63%
Revenue NY rev (3m)-9.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.61
P/FCF N/A
P/OCF N/A
P/B 9.85
P/tB 9.85
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0.72
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.19%
ROE -639.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.73%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 3.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.19%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 6.18
Altman-Z -4.57
F-Score3
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y47.38%
EPS Next 2Y37.44%
EPS Next 3Y32.85%
EPS Next 5Y24.4%
Revenue 1Y (TTM)167.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.31%
Revenue Next Year110.33%
Revenue Next 2Y93.19%
Revenue Next 3Y76.78%
Revenue Next 5Y52.16%
EBIT growth 1Y-16.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.06%
OCF growth 3YN/A
OCF growth 5YN/A